Evidence map›Paper›PMID 29246302›Full record

ReviewMolecular therapy. Nucleic acids2017

CRISPR/Cas9 Genome-Editing System in Human Stem Cells: Current Status and Future Prospects.

Zhao Zhang, Yuelin Zhang, Fei Gao, Shuo Han, Kathryn S Cheah, Hung-Fat Tse, Qizhou Lian

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular therapy. Nucleic acids, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 1 pooled it
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 1 synthesis or guideline pooled it, 108 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Zhao ZhangDepartment of Medicine, University of Hong Kong, Hong Kong, China.
Yuelin ZhangDepartment of Medicine, University of Hong Kong, Hong Kong, China.
Fei GaoDepartment of Medicine, University of Hong Kong, Hong Kong, China.
Shuo HanDepartment of Medicine, University of Hong Kong, Hong Kong, China.
Kathryn S CheahSchool of Biomedical Sciences, University of Hong Kong, Hong Kong, China.
Hung-Fat TseDepartment of Medicine, University of Hong Kong, Hong Kong, China; Shenzhen Institutes of Research and Innovation, University of Hong Kong, Shenzhen, China.
Qizhou LianDepartment of Medicine, University of Hong Kong, Hong Kong, China; Shenzhen Institutes of Research and Innovation, University of Hong Kong, Shenzhen, China; School of Biomedical Sciences, University of Hong Kong, Hong Kong, China. Electronic address: qzlian@hku.hk.
University of Hong Kong · HKCity University of Hong Kong, Shenzhen Research Institute · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genome-editing involves the insertion, deletion, or replacement of DNA in the genome of a living organism using "molecular scissors." Traditional genome editing with engineered nucleases for human stem cells is limited by its low efficiency, high cost, and poor specificity. The CRISPR system has recently emerged as a powerful gene manipulation technique with advantages of high editing efficiency and low cost. Although this technique offers huge potential for gene manipulation in various organisms ranging from prokaryotes to higher mammals, there remain many challenges in human stem cell research. In this review, we highlight the basic biology and application of the CRISPR/Cas9 system in current human stem cell research, discuss its advantages and challenges, and debate the future prospects for human stem cells in regenerative medicine.

Indexed as

applicationschallengesCRISPR/Cas9human stem cellsprospects

Identifiers

PMID29246302
PMCPMC5651489
OpenAlexW2761178778

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.